



DATE: 29.07.2024

To,
The Manager,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai-400001

Script Code: 539206

Symbol: GVBL

Subject: Outcome of the Board Meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on today i.e., 29th July, 2024

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at their meeting held on Monday, 29th July, 2024, at the Corporate Office of the Company inter-alia to transact the following business items with the permission of the Chair, if any:

1. Considered and approved the standalone Un-Audited financial results of the Company for the quarter ended 30th June, 2024. A copy of the said standalone un-audited financial results along with the Limited review report from statutory auditor is enclosed herewith.

The meeting of the Board of Directors commenced at 5:00 PM. and concluded at 5:35 PM.

This is for your information and record.

Thanking you,
Yours Faithfully,

For and on behalf of
Genomic Valley Biotech Limited

YOGESH
AGRAWAL

Digitally signed by
YOGESH AGRAWAL
Date: 2024.07.29
17:46:07 +05'30'

Yogesh Agrawal
Managing Director
DIN: 01165288
Place: Delhi

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter ended on
June 30, 2024 and year to date from April 01, 2024 to June 30, 2024**

We have reviewed the accompanying statement of unaudited financial results for **the Quarter ended on June 30, 2024 and year to date from April 01, 2024 to June 30, 2024** ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ANDROS & CO.
Chartered Accountants
FRN :0008976N



Bhavuk Garg
(CA Bhavuk Garg) (Partnership Firm)
(Membership No.-502310)

Place: Delhi
Date: 29.07.2024
UDIN:

UDIN: 24502310-BJZYPL-6922

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Genomic Valley Biotech Limited today reported its financial performance for the quarter and nine months ended
30 June 2024

Highlights of the Un-Audited Financial Results as compared to the previous year are:

Part I

In Rs.

Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous year ended
		30-Jun-24	31-Mar-24	30-Jun-23	31-Mar-24
		Un-Audited	Audited	Un-Audited	Audited
I	Revenue From Operations	15,53,350	-	5,85,500	16,50,750
II	Other Income	-	-	15,002	15,003
III	Total Revenue (I+II)	15,53,350	-	6,00,502	16,65,753
IV	Expenses				
	Cost of materials consumed	-	-	-	-
	Purchases of Stock-in-Trade	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-
	Employee benefits expense	1,20,000	45,000	1,95,000	3,75,000
	Financial costs	-	-	-	-
	Depreciation and amortization expense	-	2,732	2,731	10,925
	Other expenses	1,57,447	3,98,600	1,34,666	11,28,348
	Total Expenses (IV)	2,77,447	4,46,332	3,32,397	15,14,273
V	Profit / (Loss) before exceptional item and tax (III-IV)	12,75,903	-4,46,332	2,68,105	1,51,480
VI	Exceptional Item	-	-	-	-
VII	Profit/loss before Tax (V-VI)	12,75,903	-4,46,332	2,68,105	1,51,480
VIII	Tax expenses				
	(1) Current Tax	-	-	-	-
	(2) Deferred Tax	-	-339	-	-339
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	12,75,903	-4,45,993	2,68,105	1,51,818
X	Profit/ (Loss) from discontinued operations	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	12,75,903	-4,45,993	2,68,105	1,51,818
XIV	Other Comprehensive Income	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	12,75,903	-4,45,993	2,68,105	1,51,818
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	30,54,500	30,54,500	30,54,500	30,54,500
XVII	Earning Per Equity Share (for continuing operation):				
	1) Basic	0.42	-0.15	0.09	0.05
	2) Diluted	0.42	-0.15	0.09	0.05
XVIII	Earning Per Equity Share (for discontinued operation):				
	1) Basic	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):				
	1) Basic	0.42	-0.15	0.09	0.05
	2) Diluted	0.42	-0.15	0.09	0.05

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on .29th July 2024. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Comapnies Act, 2013 and other accounting principles generally accepted in India.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited

YOGESH
AGRAWAL

Yogesh Agrawal

(Managing Director)

DIN-01165288

Place : Delhi
Dated : 29/07/2024

Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063